Document Detail

One year growth hormone replacement therapy does not alter colonic epithelial cell proliferation in growth hormone deficient adults.
MedLine Citation:
PMID:  10762288     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Increased colonic epithelial cell proliferation has been found in various conditions associated with increased risk of colorectal cancer including acromegaly. In a placebo-controlled study we determined the effect of growth hormone (GH) replacement therapy in GH deficient adults on the colonic epithelial proliferation rate. PATIENTS AND DESIGN: Sixteen GH deficient adults were randomised to low dose GH therapy (1 U (0.5 mg) subcutaneously per day, n = 5), high dose GH therapy (2 U daily, n = 5) or placebo (n = 6) during 6 months. Thereafter, all patients were treated with 2 U of GH daily during a 6-months open extension period. MEASUREMENTS: Plasma Insulin-like growth hormone I (IGF-I) and IGF binding protein 3 (IGF BP3) concentrations were measured using commercial RIA kits. The colonic epithelial proliferation rate, expressed as overall crypt labelling index (LI) using 5-bromo-2'-deoxyuridine (BrdU) immunostaining, was determined at baseline, after 6 months treatment and at the end of the 6 months open extension period. RESULTS: IGF-I rose from 8.9 +/- 6.7 to 34.6 +/- 20.0 nmol/l after 6 months in 8 GH treated patients (P < 0.01 from baseline; P < 0.01 from change with placebo). In the extension study, plasma IGF-I was also increased in the patients who previously received placebo (P < 0.02, n = 5). LI was evaluable in 14 biopsies at baseline, in 16 after 6 months and in 14 after 12 months. Overall crypt LI did not change in 8 GH treated patients after 6 months (P > 0.40 from baseline; P > 0.80 from change with placebo). In the extension study, overall crypt LI was also unchanged in those patients who received GH after placebo (n = 5, P > 0.40) and in those who continued GH replacement (n = 9, P > 0.60; P > 0.80 from change in initially placebo treated patients). Separate evaluation of the LI at the basal, mid and luminal portions of the colonic crypts also did not reveal any effect of GH treatment on BrdU labelling. CONCLUSIONS: Six to 12 months of GH replacement therapy, aimed to increase plasma IGF-I into the (high) physiological range, does not adversely affect colonic epithelial cell proliferation as a biomarker for the risk of development of colorectal cancer.
J A Beentjes; B A van Gorkom; W J Sluiter; E G de Vries; J H Kleibeuker; R P Dullaart
Related Documents :
9173938 - Weight loss and wrestling training: effects on growth-related hormones.
9210208 - The stability of plasma growth hormone and mhpg responses to repeated clonidine challen...
2827218 - Gonadal steroids do not affect basal growth hormone response to naloxone in humans.
2380338 - Acute clonidine administration potentiates spontaneous diurnal, but not nocturnal, grow...
6782838 - Serum prolactin and thyrotropin responses to thyrotropin-releasing hormone in men with ...
16728048 - Peripheral inhibin levels in relation to climatic variations and stage of estrous cycle...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical endocrinology     Volume:  52     ISSN:  0300-0664     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  2000 Apr 
Date Detail:
Created Date:  2000-06-13     Completed Date:  2000-06-13     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  457-62     Citation Subset:  IM    
Department of Internal Medicine, Divisions of; Endocrinology, University Hospital Groningen, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cell Division / drug effects
Colon / drug effects,  pathology*
Colonic Neoplasms / etiology
Epithelial Cells / drug effects,  pathology
Growth Hormone / adverse effects,  deficiency*,  therapeutic use
Hormone Replacement Therapy*
Middle Aged
Risk Factors
Reg. No./Substance:
9002-72-6/Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiog...
Next Document:  Analysis of the intracellular signalling domain of the human growth hormone receptor in children wit...